Bioequivalence Study of Zidovudine 300 mg Tablets, USP Under Fed Conditions

Ranbaxy

Status: Completed

Conditions: Healthy

Treatments: Drug: Zidovudine 300mg tablets

Study type: Interventional

Funder types: Industry

Identifiers

NCT00779376

AA26101

Details and patient eligibility

About

The objective of this study was to assess the single-dose relative bioavailability of Ranbaxy and GlaxoSmithKline (Retrovir ®) 300 mg Zidovudine tablets, under fed conditions

Full description

This was an open label, randomized, single dose, 2-way crossover, comparative bioavailability study performed on 68 healthy adult volunteers. In each period, subjects were housed from at least 10 hours before dosing until after the 12 hour blood draw. Single oral dose 300 mg Zidovudine doses were separated by a washout period of 7 days.

A total of sixty-eight (68) healthy adult subjects (29 males and 39 females) were enrolled in the study, of which sixty five (65) subjects (29 males and 36 females) completed the clinical portion of the study.

Enrollment: 68 patients

Sex: All

Ages: 18 to 55 years old

Volunteers: Accepts Healthy Volunteers

Inclusion criteria

1. Healthy adult male or female volunteers, 18-55 years of age

2. Weighing at least 52 kg for males and 45 kg for females within 15 % of their ideal weights (table of 'Desirable weights of Adults', Metropolitan Life Insurance Company, 1983)

3. Medically healthy subjects with clinically normal laboratory profiles, vital signs and ECGs

4. Females of child bearing potential were either sexually inactive (abstinent) for 14 days prior to the first dose and throughout the study or were using one of the following acceptable birth control methods:

   Surgically sterile (bilateral tubal ligation, hysterectomy, bilateral oophorectomy) 6 months minimum; IUD in place for at least 3 months; Barrier methods (condom, diaphragm) with spermicide for at least 14 days prior to the first dose and throughout the study Surgical sterilization of the partner (vasectomy for 6 months minimum) Hormonal contraception for at least 3 months prior to the first dose of the study Other birth control method deemed acceptable

5. Postmenopausal women with amenorrhea for at least 2 years

6. Given voluntary written informed consent to participate in this study.

Exclusion criteria

1. History or presence of significant cardiovascular, pulmonary, hepatic, renal, hematologic, gastrointestinal, endocrine, immunologic, dermatologic, neurologic or psychiatric disease
2. In addition history or presence of alcoholism or drug abuse within the past year, or hypersensitivity or idiosyncratic reaction to Zidovudine or to any other nucleoside analogue
3. Female subjects who were pregnant or lactating
4. Subjects who tested positive at screening for HIV, HBsAg or HCV
5. Subjects who have used any drugs or substances known to be strong inhibitors of cyp enzymes (formerly known as cytochrome p 450 enzymes) within 10 days prior to the first dose
6. Subjects who have used any drugs or substances known to be strong inducers of cyp enzymes (formerly known as cytochrome P 450 enzymes) within 28 days prior to the first dose and throughout the study
7. Subjects who through completion of the study would have donated in excess of 500 mL of blood in 14 days, 1500 mL of blood in 180 days or 2500 mL of blood in 1 year
8. Subjects who have participated in another clinical trial within 28 days prior to the first dose.

Trial design

68 participants in 2 patient groups

1

Experimental group

Description:

Zidovudine 300mg tablets of Ranbaxy

Treatment:

Drug: Zidovudine 300mg tablets

2

Active Comparator group

Description:

Retrovir ®) 300 mg Zidovudine tablets of Glaxosmithkline

Treatment:

Drug: Zidovudine 300mg tablets